We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allscripts Rides High on Product Launches Amid Rising Costs
Read MoreHide Full Article
On Sep 22, we issued an updated research report on Allscripts Healthcare Solutions Inc. (MDRX - Free Report) . The company has been on a healthy growth trajectory of late. It has rallied 14.2% in the last one year, ahead of the S&P 500’s 11% gain. This Zacks Rank #3 (Hold) stock has a market cap of $2.47 billion.
Allscripts Healthcare provides information technology (IT) solutions and services to healthcare organizations.Higher adoption of the company’s EHR solutions, particularly the Sunrise EHR platform, will consistently drive the company’s top line and help it to counter stiff competition in the long run.
In an initiative to eradicate ambiguity while determining medicinal costs and discounts, Allscripts recently launched Allscripts Real-Time Health System, an exclusive work-flow solution to optimize the clinical and financial impact of medical prescriptions and enhance prescription price transparency.
With the latest launch, Allscripts aims at providing clinicians and patients with complete information on medication price, cost of alternative therapies, and competitive prices of the prescribed therapy at different pharmacies. Notably, Allscripts is the first major healthcare information technology player to come up with such a solution.
On the flipside, the company expects a modest increase in operating expenses during the second half of 2017. Allscripts’ products have a long sales cycle which involves decision-making at different managerial levels. This increases the company’s operating expenses.
Added to this, the lingering global economic weakness presents a substantial risk for Allscripts. Unlike the manufacturers of life-saving devices, the demand for the software company’s products is closely tied to budgetary processes of clients. As a result, the company has seen a significant decline in system sales due to a decline in customer orders.
Key Picks
A few better-ranked stocks in the broader medical sector are Edwards Lifesciences Corp. (EW - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Cogentix Medical, Inc. (CGNT - Free Report) .
Edwards Lifesciences delivered an average earnings beat of 10.8% over the last four quarters. The company has a long-term expected earnings growth rate of 15.2%.
IDEXX Laboratories delivered an average earnings beat of 9.3% over the trailing four quarters. It has a long-term expected earnings growth rate of 19.8%.
Cogentix Medical came up with a positive earnings surprise of 200% in the last quarter. The stock represented a stellar return of 100.9% over the last year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Allscripts Rides High on Product Launches Amid Rising Costs
On Sep 22, we issued an updated research report on Allscripts Healthcare Solutions Inc. (MDRX - Free Report) . The company has been on a healthy growth trajectory of late. It has rallied 14.2% in the last one year, ahead of the S&P 500’s 11% gain. This Zacks Rank #3 (Hold) stock has a market cap of $2.47 billion.
Allscripts Healthcare provides information technology (IT) solutions and services to healthcare organizations.Higher adoption of the company’s EHR solutions, particularly the Sunrise EHR platform, will consistently drive the company’s top line and help it to counter stiff competition in the long run.
In an initiative to eradicate ambiguity while determining medicinal costs and discounts, Allscripts recently launched Allscripts Real-Time Health System, an exclusive work-flow solution to optimize the clinical and financial impact of medical prescriptions and enhance prescription price transparency.
With the latest launch, Allscripts aims at providing clinicians and patients with complete information on medication price, cost of alternative therapies, and competitive prices of the prescribed therapy at different pharmacies. Notably, Allscripts is the first major healthcare information technology player to come up with such a solution.
Allscripts Healthcare Solutions, Inc. Price
Allscripts Healthcare Solutions, Inc. Price | Allscripts Healthcare Solutions, Inc. Quote
On the flipside, the company expects a modest increase in operating expenses during the second half of 2017. Allscripts’ products have a long sales cycle which involves decision-making at different managerial levels. This increases the company’s operating expenses.
Added to this, the lingering global economic weakness presents a substantial risk for Allscripts. Unlike the manufacturers of life-saving devices, the demand for the software company’s products is closely tied to budgetary processes of clients. As a result, the company has seen a significant decline in system sales due to a decline in customer orders.
Key Picks
A few better-ranked stocks in the broader medical sector are Edwards Lifesciences Corp. (EW - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Cogentix Medical, Inc. (CGNT - Free Report) .
Notably, Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while IDEXX Laboratories and Cogentix Medical have a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences delivered an average earnings beat of 10.8% over the last four quarters. The company has a long-term expected earnings growth rate of 15.2%.
IDEXX Laboratories delivered an average earnings beat of 9.3% over the trailing four quarters. It has a long-term expected earnings growth rate of 19.8%.
Cogentix Medical came up with a positive earnings surprise of 200% in the last quarter. The stock represented a stellar return of 100.9% over the last year.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>